Abstract
Precision health is an unrealized opportunity in the practice and care of stroke patients. To achieve truly person-centered care as the Precision Medicine Initiative (PMI) outlines, a new approach to stroke research is necessary. Multi-omic profiling of the immune system response to human stroke provides a significant advantage over single system and/or multibiomarker analyses. By combining powerful ‘omic’ technologies with machine learning and pattern recognition for interpretation of this multi-omic data, we are better able to understand the complexity of stroke physiology. These measurements allow for new methods in the diagnosis, treatment stratification, and design of personalized approaches to stroke recovery. The foundation by which these novel approaches can be utilized to understand human stroke complexity and translated into programs of research and clinical practice paradigms is being created, and will ultimately change the way we diagnosis and treat stroke patients. This review will briefly outline current approaches and how to leverage these discoveries to achieve person-centered stroke care.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ding K, Wu S, Ying W, Pan Q, Li X, Zhao D et al (2015) Leveraging a multi-omics strategy for prioritizing personalized candidate mutation-driver genes: a proof-of-concept study. Sci Rep 5:17564
Kim ST, Lee J, Hong M, Park K, Park JO, Ahn T et al (2015) The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. Oncotarget 6(32):33358–33368
Pineda S, Gomez-Rubio P, Picornell A, Bessonov K, Marquez M, Kogevinas M et al (2015) Framework for the Integration of Genomics, Epigenomics and Transcriptomics in Complex Diseases. Hum Hered 79(3-4):124–136
Wang L, Xiao Y, Ping Y, Li J, Zhao H, Li F et al (2014) Integrating multi-omics for uncovering the architecture of cross-talking pathways in breast cancer. PLoS One 9(8), e104282
Sandercock PA (2015) Does personalized medicine exist and can you test it in a clinical trial? Int J Stroke 10(7):994–999
Yu KH, Snyder M (2016) Omics profiling in precision oncology. Mol Cell Proteomics 15(8):2525–2536
Greenplate AR, Johnson DB, Ferrell PB Jr, Irish JM (2016) Systems immune monitoring in cancer therapy. Eur J Cancer 61:77–84
Boskovic A, Belada N, Knezevic B (2014) Prognostic value of heart rate variability in post-infarction patients. Vojnosanit Pregl 71(10):925–930
Song T, Qu XF, Zhang YT, Cao W, Han BH, Li Y et al (2014) Usefulness of the heart-rate variability complex for predicting cardiac mortality after acute myocardial infarction. BMC Cardiovasc Disord 14:59
Benoist C, Germain RN, Mathis D (2006) A plaidoyer for ‘systems immunology’. Immunol Rev 210:229–234
Lo EH, Ning M (2016) Mechanisms and challenges in translational stroke research. J Investig Med 64(4):827–829
Famakin BM (2014) The immune response to acute focal cerebral ischemia and associated post-stroke immunodepression: a focused review. Aging Dis 5(5):307–326
Brooks SD, Spears C, Cummings C, VanGilder RL, Stinehart KR, Gutmann L et al (2014) Admission neutrophil-lymphocyte ratio predicts 90 day outcome after endovascular stroke therapy. J Neurointerv Surg 6(8):578–583
Celikbilek A, Ismailogullari S, Zararsiz G (2014) Neutrophil to lymphocyte ratio predicts poor prognosis in ischemic cerebrovascular disease. J Clin Lab Anal 28(1):27–31
Holt RA (2015) Immunogenomics: a foundation for intelligent immune design. Genome Med 7(1):116
Martino D, Allen K (2015) Meeting the challenges of measuring human immune regulation. J Immunol Methods 424:1–6
Amantea D, Bagetta G (2016) Drug repurposing for immune modulation in acute ischemic stroke. Curr Opin Pharmacol 26:124–130
Fu Y, Liu Q, Anrather J, Shi FD (2015) Immune interventions in stroke. Nat Rev Neurol 11(9):524–535
Allen S, Liu YG, Scott E (2016) Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis. Regen Eng Transl Med 2(1):37–50
Wu CC, Chen BS (2016) Key immune events of the pathomechanisms of early cardioembolic stroke: multi-database mining and systems biology approach. Int J Mol Sci 17(3):305
Wong YH, Wu CC, Lai HY, Jheng BR, Weng HY, Chang TH et al (2015) Identification of network-based biomarkers of cardioembolic stroke using a systems biology approach with time series data. BMC Syst Biol 9(Suppl 6):S4
Bielekova B, Vodovotz Y, An G, Hallenbeck J (2014) How implementation of systems biology into clinical trials accelerates understanding of diseases. Front Neurol 5:102
Ren C, Guingab-Cagmat J, Kobeissy F, Zoltewicz S, Mondello S, Gao M et al (2014) A neuroproteomic and systems biology analysis of rat brain post intracerebral hemorrhagic stroke. Brain Res Bull 102:46–56
Libbrecht MW, Noble WS (2015) Machine learning applications in genetics and genomics. Nat Rev Genet 16(6):321–332
Konig IR, Auerbach J, Gola D, Held E, Holzinger ER, Legault MA et al (2016) Machine learning and data mining in complex genomic data-a review on the lessons learned in Genetic Analysis Workshop 19. BMC Genet 17(Suppl 2):1
Petrone AB, O’Connell GC, Regier MD, Chantler PD, Simpkins JW, Barr TL (2016) The role of Arginase 1 in post-stroke immunosuppression and ischemic stroke severity. Transl Stroke Res 7(2):103–110
Wasserstein RL, Lazar NA (2016) The ASA’s statement on p-values: context, process, and purpose. The American Statistician. pp 129-133. http://dx.doi.org/10.1080/00031305.2016.1154108
Mamoshina P, Vieira A, Putin E, Zhavoronkov A (2016) Applications of deep learning in biomedicine. Mol Pharm 13(5):1445–1454
Yip KY, Cheng C, Gerstein M (2013) Machine learning and genome annotation: a match meant to be? Genome Biol 14(5):205
Karlinski M, Gluszkiewicz M, Czlonkowska A (2015) The accuracy of prehospital diagnosis of acute cerebrovascular accidents: an observational study. Arch Med Sci 11(3):530–535
Newman-Toker DE, Ernest M, Ernest V, Rosanna C, Hines AL (2014) Missed diagnosis of stroke in the emergency department: a cross-sectional analysis of a large population-based sample. Diagnosis 1(2):155–166. doi:10.1515/dx-2013-0038
National Academies of Sciences E and Medicine (2015) Improving diagnosis in health care. The National Academies Press, Washington, DC
Gelabert MA (1990) [Infections caused by gram positive bacteria: a new epidemics in patients with positive anti-HIV antibodies and drug addicts]. Arch Esp Urol 43(2):103–105
Barr TL, Conley Y, Ding J, Dillman A, Warach S, Singleton A et al (2010) Genomic biomarkers and cellular pathways of ischemic stroke by RNA gene expression profiling. Neurology 75(11):1009–1014
Barr TL, VanGilder R, Rellick S, Brooks SD, Doll DN, Lucke-Wold AN et al (2015) A genomic profile of the immune response to stroke with implications for stroke recovery. Biol Res Nurs 17(3):248–256
Yang J, Luo X, Huang X, Ning Q, Xie M, Wang W (2014) Ephrin-A3 reverse signaling regulates hippocampal neuronal damage and astrocytic glutamate transport after transient global ischemia. J Neurochem 131(3):383–394
Six A, Mariotti-Ferrandiz ME, Chaara W, Magadan S, Pham HP, Lefranc MP et al (2013) The past, present, and future of immune repertoire biology - the rise of next-generation repertoire analysis. Front Immunol 4:413
Peterson-Burch FR-R, K; Barr, TL (2017) Rethinking Recovery: Incorporating Holistic Nursing Perspectives in Post-Stroke Care, Holistic Nursing Practice, In Press, 2017
Hatfield I, Allison A, Flight L, Julious SA, Dimairo M (2016) Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials 17(1):150
Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M et al (2012) Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657. J Clin Oncol 30(26):3242–3249
Printz C (2013) I-SPY 2 may change how clinical trials are conducted: researchers aim to accelerate approvals of cancer drugs. Cancer 119(11):1925–1927
Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ (2009) I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86(1):97–100
Yuan Y, Guo B, Munsell M, Lu K, Jazaeri A (2016) MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Stat Med. doi:10.1002/sim.6971
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A et al (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1(1):44–53
Antoniou M, Jorgensen AL, Kolamunnage-Dona R (2016) Biomarker-guided adaptive trial designs in Phase II and Phase III: a methodological review. PLoS One 11(2), e0149803
Collette L, Tombal B (2015) N-of-1 trials in oncology. Lancet Oncol 16(8):885–886
Vohra S, Shamseer L, Sampson M, Bukutu C, Schmid CH, Tate R, CONSORT extension for reporting N-of-1 trials (CENT) et al (2015) Statement. J Clin Epidemiol 2015
Sieverink F, Siemons L, Braakman-Jansen A, van Gemert-Pijnen L (2016) Internet of things & personalized healthcare. Stud Health Technol Inform 221:129
Godbehere P, Wareing P (2014) Hypertension assessment and management: role for digital medicine. J Clin Hypertens (Greenwich) 16(3):235
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Barr, T.L., Gionis, V., Giersch, R. (2017). Harnessing the Power of the Human Immune System via Multi-omic Immune Profiling in Stroke Treatment and Recovery. In: Lapchak, P., Zhang, J. (eds) Neuroprotective Therapy for Stroke and Ischemic Disease. Springer Series in Translational Stroke Research. Springer, Cham. https://doi.org/10.1007/978-3-319-45345-3_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-45345-3_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-45344-6
Online ISBN: 978-3-319-45345-3
eBook Packages: MedicineMedicine (R0)